Sanofi is betting big on a promising new platform to develop ‘super antibodies’ which could open up new possibilities in oncology, immunology and inflammation, via a partnership with IGM Biosciences potentially worth more than $6bn in milestones.
The partnership kicks off with a $150m upfront payment, with the French pharma company also expressing an interest in buying up to $100m of IGM Biosciences’s non-voting common stock in a